Leading the way in Europe to bring
microbiome-based innovations to market.

LD75 Web Print logo Blanc EMIH

European Microbiome Innovation for Health (EMIH) brings together innovative leading European stakeholders dedicated to advancing the microbiome industry.

Our mission

The goal of the EMIH is to promote medical innovation, based on the microbiota, as one of the public health priorities within the European Union. Its members are committed to developing advances in therapeutic, diagnostics and medical bioproduction based on the microbiota, in the field of human health, through a framework meeting the highest quality standards and also allowing economic balance, in order to maintain therapeutic innovation.

About us

EMIH gathers more than 20 key private and public players supporting each other’s efforts to develop tomorrow’s medicine based on microbiome diagnostic and therapeutic innovations.

> MORE

about us apm
white form apm

EMIH is collectively building a dynamic ecosystem to advance medical innovation centered on the microbiota, prioritizing public health within the EU and addressing unmet medical needs to enhance the quality of life for millions of patients.

Our members

EMIH brings together more than 25+ key private and public players committed to develop tomorrow’s medicine based on microbiome diagnostic and therapeutic innovations.

being a member

Join us!

Unity is strength. Joining EMIH means being able to provide input to policy makers, patients’ associations, investors in Europe, and share networking opportunities while contributing to structure the industry.

News

white form apm
News
04/09/2025
MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline
> READ
white form apm
News
21/07/2025
EMIH response to the European Commission call for evidence on the EU Biotech Act
> READ
white form apm
News
10/06/2025
The “Microbiome Times Forum” brought together key experts to shape the future of microbiome innovation in the European Union
> READ

EMIH response to the European Commission call for evidence on the EU Biotech Act